Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of April 2020. The company is a foreign private issuer based in Jerusalem, Israel, focused on vaccine development, specifically its candidate M-001.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification regarding a delay in the filing of the Annual Report on Form 20-F for the year ended December 31, 2019, rather than a financial results report.
Material Changes and Operational Impact
- Reporting Delay: The company is utilizing an SEC order to delay its Form 20-F filing until June 14, 2020, due to COVID-19 disruptions in Israel affecting travel, facility access, and management resources.
- Clinical Trial Status: The Phase 3 trial for M-001 is ongoing. The company continues to collect swab samples despite restrictions. The Contract Research Organization (CRO) and statistician expect to reach the targeted number of samples if the pandemic does not significantly deteriorate.
- NIH Phase 2 Trial: The clinical portion of the Phase 2 trial conducted by the U.S. National Institutes of Health (NIH) is complete, with data published in January 2020. The publication of the Clinical Study Report (CSR) by the NIH may be impacted by the pandemic.
Guidance, Outlook, and Risks
Outlook: Management intends to publish Phase 3 trial results by the end of 2020, though they cannot guarantee this timeline will not be delayed by the pandemic. There is uncertainty regarding FDA review timelines for a potential New Drug Application (NDA) due to regulatory resource prioritization.
Risks and Contingencies:
- COVID-19 Impact: Public health emergencies could adversely impact business operations, clinical trials, and financial condition.
- Regulatory Delays: Potential interruptions in FDA operations could delay NDA review and approval.
- Capital Adequacy: The company notes risks regarding the adequacy of available cash resources and the ability to raise additional capital.
- Forward-Looking Statements: Results may differ materially from expectations due to risks related to trial prosecution, regulatory approval, and intellectual property.
Investor Verification Checklist
- Verify the actual filing date of the delayed Form 20-F (expected by June 14, 2020) to obtain audited financial data.
- Monitor updates on the Phase 3 M-001 trial sample collection rates and the anticipated release date of top-line results.
- Assess the status of the NIH Clinical Study Report (CSR) publication for the Phase 2 trial.
- Review the company's cash runway and capital raising activities in light of the stated risk regarding available resources.
- Confirm any changes to the FDA review timeline for the M-001 NDA.